Monitoring CIDP Treatment Response with Objective Outcome Measures

In "Monitoring CIDP Treatment Response with Objective Outcome Measures," our panel explores the critical role of objective outcome measures in assessing treatment response, guiding therapy adjustments, and detecting relapse in patients with CIDP. Panelists emphasize that patient-reported improvement alone is insufficient and should be supported by standardized, reproducible clinical assessments repeated at every visit.

A range of tools is discussed, including MRC strength scores, timed vibration testing, deep tendon reflexes, grip strength dynamometry, and validated disability scales such as the I-RODS and INCAT. The timed up and go test and a neuropathy function scale validated in amyloid neuropathy studies — involving heel-and-toe walking and rising from one knee — are highlighted as practical functional assessments. One panelist, approaching monitoring from an electrophysiologic perspective, advocates for serial nerve conduction studies and peripheral nerve ultrasound to objectively confirm clinical improvement, noting that resolution of conduction block and recovery of motor response amplitude can be both reassuring and predictive of continued progress.

Panelists discuss how tracking these measures over time informs decisions about dose optimization, therapy switching, and potential tapering, while also helping patients appreciate their own functional gains. The challenge of distinguishing treatment-driven stability from natural disease plateau is acknowledged as a recurring clinical dilemma.

Regarding monitoring frequency, panelists generally recommend three-month assessment intervals following any treatment adjustment, extending to four-to-six months for stable patients. When transitioning to an FcRn antagonist specifically, an earlier one-month check-in is suggested to confirm tolerability and early treatment trajectory before returning to the standard three-month schedule.

Our next episode, "Setting Treatment Goals and Managing Expectations in CIDP," features panelists defining realistic treatment goals for newly diagnosed and chronic CIDP patients, addressing the frequent misalignment between patient and clinician expectations regarding the timing and depth of treatment response, and emphasizing the importance of early and ongoing communication about residual deficits and the meaning of remission.